Refine
Has Fulltext
- yes (16)
Is part of the Bibliography
- yes (16)
Year of publication
Document Type
- Journal article (15)
- Conference Proceeding (1)
Language
- English (16) (remove)
Keywords
- Neuroendocrine Tumor (2)
- Oncology (2)
- PRRT (2)
- Positronen-Emissions-Tomografie (2)
- Radionuclide Therapy (2)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18F-FDG (1)
- 18F-FDG PET/CT (1)
- 1st International Workshop (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2015 (1)
- 5IA-SPECT (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-PSMA ligand PET/CT (1)
- Antibodies (1)
- B-cell lymphoma (1)
- Cardiology (1)
- Conjugate arc therapy (1)
- EANM (1)
- FDG (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- GI (1)
- Gastrointestinal (1)
- Hamburg (1)
- Highlights Lecture (1)
- Hodgkin-lymphoma (1)
- MIBG scintigraphy (1)
- Medullärer Schilddrüsenkrebs (1)
- Molecular Imaging (1)
- Myeloma cells (1)
- Myelomas (1)
- Myocardial perfusion (1)
- Neuroendocrine (1)
- Neurosciences (1)
- PET (1)
- PET/CT (1)
- Parkinson disease (1)
- Parkinson's disease (1)
- Phase-II (1)
- Physics and instrumentation (1)
- Positron emission tomography (1)
- Preclinical evaluation (1)
- Primary hyperparathyroidism (pHPT) (1)
- Prostate-cancer (1)
- RADS (1)
- Radionuclide therapy (1)
- Radiopharmacy (1)
- SPECT (1)
- SSTR (1)
- Standardisierung (1)
- Targeted therapy (1)
- Thyroid cancer (1)
- WB-DW-MRI (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [18F]FDG-PET-CT (1)
- [99mTc]-Sestamibi scan (1)
- abdominal lymph node metastases (1)
- adenocarcinoma of the lung (1)
- androgen deprivation therapy (1)
- angiogenesis (1)
- antidepressant (1)
- benzylguanidine (1)
- biosynthesis (1)
- bone marrow cells (1)
- cancer treatment (1)
- cell staining (1)
- coefficient (1)
- cognitive decline (1)
- collagens (1)
- detection rate (1)
- diagnostics (1)
- diffusion weighted MRI (1)
- diffusion weighted mri (1)
- dopamine acetylcholine (1)
- extracellular matrix (1)
- extramedullary hematopoiesis (1)
- focused surgical approach (1)
- high risk (1)
- imaging (1)
- immune check inhibitor (1)
- immune infiltration (1)
- initial experience (1)
- involvement (1)
- lesions (1)
- lung and intrathoracic tumors (1)
- lymphoma (1)
- mRNA (1)
- machine learning (1)
- malignant lymphoma (1)
- medullary thyroid carcinoma (1)
- miRNA (1)
- molecular diagnostics (1)
- multiple myeloma (1)
- multiple system atrophy (1)
- nicotinic receptors (1)
- norepinephrine transporter (1)
- organic cation transporter (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- pembrolizumab (1)
- peripheral nervous system (1)
- phenethylguanidine (1)
- positron emission tomography (1)
- preoperative localization (1)
- primary hyperparathyroidism (1)
- pulmonary imaging (1)
- recurrent prostate cancer (1)
- repeat surgery (1)
- repeated surgery (1)
- response evaluation (1)
- secondary lung tumors (1)
- skin biopsy (1)
- spleen (1)
- theranostics (1)
- trachea (1)
- transcriptome (1)
- tumor burden (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (1)
- vandetanib (1)
- whole body MRI (1)
- whole-body (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (16)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Medizinische Klinik und Poliklinik I (3)
- Medizinische Klinik und Poliklinik II (3)
- Pathologisches Institut (3)
- Neurologische Klinik und Poliklinik (2)
- Urologische Klinik und Poliklinik (2)
- Center for Computational and Theoretical Biology (1)
- Comprehensive Cancer Center Mainfranken (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (3)
Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy.
Introduction: Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKI). We
aimed to assess the role of metabolic imaging using 2-deoxy-2-(\(^{18}\)F)fluoro-D-glucose (\(^{18}\)F-FDG) positron emission tomography/computed tomography (PET/CT) shortly before and 3 months after initiation of TKI treatment.
Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline \(^{18}\)F-FDG PET/CT prior to and 3 months after TKI treatment initiation. During follow-up, CT scans were performed every 3 months and analyzed according to Response Evaluation Criteria In Solid Tumors (RECIST). The predictive value for estimating progression-free (PFS) and overall survival (OS) was examined by investigating \(^{18}\)F-FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET (rearranged during transfection) mutational status, and disease type).
Results: Within a median follow-up of 5.2 years, 9 patients experienced disease progression after a median time interval of 2.1y whereas the remainder had ongoing disease control (n=5 partial response and n=4 stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5y after TKI initiation.
Pre-therapeutic SUVmean >4.0 predicted a significantly shorter PFS (PFS: 1.9y vs. 5.2y; p=0.04). Furthermore, sustained high 18F-FDG uptake at 3 months with a SUVmean>2.8 tended to portend an unfavorable prognosis with a PFS of 1.9y (vs. 3.5y; p=0.3). Prolonged CEA doubling times were significantly correlated with longer PFS (r=0.7) and OS (r=0.76, p<0.01, respectively). None of the other clinical parameters had prognostic significance.
Conclusions: Pre-therapeutic \(^{18}\)F-FDG PET/CT holds prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. Low tumor metabolism of SUVmean < 4.0 prior to treatment predicts longer progression-free survival.
Background: Use of FDG-PET/CT for staging and restaging of lymphoma patients is widely incorporated into current practice guidelines. Our aim was to prospectively evaluate the diagnostic performance of FDG-PET/MRI and WB-DW-MRI compared with FDG-FDG-PET/CT using a tri-modality PET/CT-MRI system.
Methods: From 04/12 to 01/14, a total of 82 FDG-PET/CT examinations including an additional scientific MRI on a tri-modality setup were performed in 61 patients. FDG-PET/CT, FDG-PET/MRI, and WB-DW-MRI were independently analyzed. A lesion with a mean ADC below a threshold of 1.2 x 10\(^{-3}\) mm\(^2\)/s was defined as positive for restricted diffusion. FDG-PET/CT and FDG-PET/MRI were evaluated for the detection of lesions corresponding to lymphoma manifestations according to the German Hodgkin Study Group. Imaging findings were validated by biopsy (n = 21), by follow-up imaging comprising CT, FDG-PET/CT, and/or FDG-PET/MRI (n = 32), or clinically (n = 25) (mean follow-up: 9.1 months).
Results: FDG-PET/MRI and FDG-PET/CT accurately detected 188 lesions in 27 patients. Another 54 examinations in 35 patients were negative. WB-DW-MRI detected 524 lesions, of which 125 (66.5 % of the aforementioned 188 lesions) were true positive. Among the 188 lesions positive for lymphoma, FDG-PET/MRI detected all 170 instances of nodal disease and also all 18 extranodal lymphoma manifestations; by comparison, WB-DW-MRI characterized 115 (67.6 %) and 10 (55.6 %) lesions as positive for nodal and extranodal disease, respectively. FDG-PET/MRI was superior to WB-DW-MRI in detecting lymphoma manifestations in patients included for staging (113 vs. 73), for restaging (75 vs. 52), for evaluation of high-(127 vs. 81) and low-grade lymphomas (61 vs. 46), and for definition of Ann Arbor stage (WB-DW-MRI resulted in upstaging in 60 cases, including 45 patients free of disease, and downstaging in 4).
Conclusion: Our results indicate that FDG-PET/CT and FDG-PET/MRI probably have a similar performance in the clinical work-up of lymphomas. The performance of WB-DW-MRI was generally inferior to that of both FDG-PET-based methods but the technique might be used in specific scenarios, e.g., in low-grade lymphomas and during surveillance.
We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson's disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease.
Purpose
Multiple myeloma is a hematologic malignancy originating from clonal plasma cells. Despite effective therapies, outcomes are highly variable suggesting marked disease heterogeneity. The role of functional imaging for therapeutic management of myeloma, such as positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG-PET), remains to be determined. Although some studies already suggested a prognostic value of 18F-FDG-PET, more specific tracers addressing hallmarks of myeloma biology, e.g. paraprotein biosynthesis, are needed. This study evaluated the amino acid tracers L-methyl-[11C]-methionine (11C-MET) and [18F]-fluoroethyl-L-tyrosine (18F-Fet) for their potential to image myeloma and to characterize tumor heterogeneity.
Experimental Design
To study the utility of 11C-MET, 18F-Fet and 18F-FDG for myeloma imaging, time activity curves were compared in various human myeloma cell lines (INA-6, MM1.S, OPM-2) and correlated to cell-biological characteristics, such as marker gene expression and immunoglobulin levels. Likewise, patient-derived CD138+ plasma cells were characterized regarding uptake and biomedical features.
Results
Using myeloma cell lines and patient-derived CD138+ plasma cells, we found that the relative uptake of 11C-MET exceeds that of 18F-FDG 1.5- to 5-fold and that of 18F-Fet 7- to 20-fold. Importantly, 11C-MET uptake significantly differed between cell types associated with worse prognosis (e.g. t(4;14) in OPM-2 cells) and indolent ones and correlated with intracellular immunoglobulin light chain and cell surface CD138 and CXCR4 levels. Direct comparison of radiotracer uptake in primary samples further validated the superiority of 11C-MET.
Conclusion
These data suggest that 11C-MET might be a versatile biomarker for myeloma superior to routine functional imaging with 18F-FDG regarding diagnosis, risk stratification, prognosis and discrimination of tumor subtypes.